| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP of Research and Development
1 company
Francisco Silva last filed a Form 4 in October 2025, as VP of Research and Development at BRTX. From August 2019 to October 2025, the filings on record show 13 open-market purchases and 1 sale. Francisco Silva's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Francisco Silva a below-average insider score of 44/100, based on 11 past trades. Over a 12-month horizon, 18.2% of those trades were profitable, with an average 12-month return of -24.5%.
At the last filing, the largest reported position was 171,384 shares of BRTX. Net of sales, the BRTX filings show accumulation of 93,903 shares.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2019 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 20,955 | $0.24 | $5,017.95 | +59.9% | |
| Aug 30, 2019 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 18,000 | $0.28 | $4,989.50 | +105.9% | |
| Aug 26, 2019 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 7,500 | $0.27 | $2,015.00 | +78.9% | |
| Aug 22, 2019 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 17,374 | $0.26 | $4,445.80 | -397.5% |